GlassScriptPhysician profile
Amanda M Lindberg
NPI 1174764740
$4,314.98
in general payments reported to CMS, 2019-2025
33 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $256 · 2021: $151 · 2022: $488 · 2023: $359 · 2024: $950 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $655.95 | 2019-2025 | |
| Novo Nordisk INC | $491.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $373.98 | 2019-2025 | |
| Lilly USA, LLC | $338.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $327.68 | 2019-2025 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $307.10 | 2019-2024 | Airsupra, Breztri |
| Exact Sciences Corporation | $303.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $209.24 | 2019-2025 | Veozah |
| Centinel Spine, LLC | $154.71 | 2022 | |
| Abbvie INC. | $138.87 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.05 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $114.46 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $80.05 | 2022 | |
| Glaxosmithkline, LLC. | $79.69 | 2019-2025 | Shingrix, Arexvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $71.47 | 2025 | Senza |
| Abbott Laboratories | $57.23 | 2025 | Freestyle Libre 3 |
| Therapeuticsmd, INC. | $49.67 | 2019 | |
| Dexcom, INC. | $40.95 | 2024 | Dexcom G6 Transmitter |
| Phadia US INC. | $36.42 | 2024-2025 | Immunocap |
| Phathom Pharmaceuticals, INC. | $29.05 | 2024-2025 | Voquezna |
| Neurocrine Biosciences, INC. | $26.90 | 2024 | Ingrezza |
| Sumitomo Pharma America, INC. | $22.31 | 2025 | Gemtesa |
| Eisai INC. | $21.06 | 2025 | |
| Amarin Pharma, INC. | $20.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.62 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.66 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.33 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $14.75 | 2019 | |
| Vivus LLC | $13.63 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.29 | 2019 | |
| Allergan, INC. | $12.52 | 2019 | |
| Zyla Life Sciences, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lindberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.